


## BIOTECHNOLOGY IN CANADA AT A GLANCE

**Canada represents just 1.8% of the global economy yet our industry provides 4 % of global biotechnology industry revenues.<sup>1</sup>**

The Canadian biotechnology community is made up of over 1000 organisations engaged in all areas of biotechnology. The full spectrum of industry activities take place here including: research, development and commercialization of therapeutics, and biologics, vaccine development and manufacturing; clinical trials, contract research and manufacturing, renewable energy crop and fuel production; bio-product manufacturing, genetic research; vaccine development; and crop research, enhancement and commercialization. Twenty-three per cent of firms work in industrial or 'white' biotechnology; sixteen per cent in agricultural biotechnology; and per forty-six per cent in health-related biotechnology.

### BIOTECHNOLOGY COMPANIES IN CANADA

#### BY AREA OF EXPERTISE



**Total biotech development companies 668**

NOTE: Fields do not add as some companies work in multiple fields.

Eighty-one per cent of the 668 biotechnology companies in Canada are privately owned.

The majority of the sector is made up of SMEs: 52 per cent of biotechnology companies have less than 20 employees, and 86 per cent have less than 100 employees.

Over 59,000 employees work directly in Canada's biotechnology private sector. 114,000 work in the larger biotechnology community, which includes such organizations as research institutes and technology parks.

Canada's bio-based economy (our biotechnology imprint in other industries) is \$78.3 billion CDN per year, or 6.4% of Canada's GDP. This exceeds the GDP contribution of the Canadian automotive, forestry or aerospace sectors.

Canada continues to welcome agricultural biotechnology innovation: Canada remains in the top five countries growing biotech crops, with 18.8 million acres planted in 2008.<sup>3</sup>

This is an 8.5 percent increase over 2007 plantings.

## MEDIA CONTACT

Ms Kasia Majewski, Director of Communications. Tel – 613 230-8858 ext 257 Cell – 613 219-2770  
Email – [kasia.majewski@biotech.ca](mailto:kasia.majewski@biotech.ca)

#### Sources:

1. GDP 2007, PPP. July 2008. World Development Indicator Database.
2. Statistics Canada, 2007, Selected Results of the Biotechnology Use and Development Survey 2005, Catalogue no. 88F0006XIE, no. 006
3. Clive James, Global Status of Commercialized Biotech/GM Crops: 2008 Brief 39. 2008. [www.isaaa.org](http://www.isaaa.org)



## STATE OF THE INDUSTRY – BIOTECCanada PWC 2009 LIFE SCIENCES FORECAST

Highlights from this biennial report on the state of the sector include:

### Finding capital remains priority

54 percent of firms report the greatest challenge continues to be raising capital (54%), consistent with 2007 findings. 78 percent of respondents indicate the ability to access capital is the greatest challenge facing the industry overall.

### Variety of Exit Strategies

While mergers and acquisitions are considered the most likely exit scenario, firms are pursuing various strategies including partnerships, collaborations and networks: 66 percent of firms looked to mergers, while 48 percent looked to co-development partnerships and 46 percent saw future licensing and IP sales as their success strategy.

### Commercialisation and R & D

Three-quarters of firms expect to need more than two years to commercialize products currently under development. 42 percent of respondents indicate their next financing round will be spent primarily on R and D. 80 percent plan to keep their operations within Canada.

The full report is available online at [www.biotech.ca](http://www.biotech.ca)

## ABOUT BIOTECCanada [www.biotech.ca](http://www.biotech.ca)

BIOTECCanada is dedicated to the sustainable commercial development of biotechnology innovation in Canada. It is the national industry-funded association with over 250 member companies representing the broad spectrum of biotech constituents including emerging and established firms in the health, industrial, and agricultural sectors, as well as academic and research institutions and other related organizations.

